Autosomal Dominant Hypocalcemia (ADH)
Pipeline by Development Stage
Competitive Landscape
2 companies ranked by most advanced pipeline stage
Trial Timeline
Clinical trial activity over time
Clinical Trials (5)
Total enrollment: 260 patients across 5 trials
Efficacy, Safety, and Tolerability of Encaleret in Participants With Chronic Hypoparathyroidism
Efficacy and Safety of Encaleret Compared to Standard of Care in Participants With ADH1
PTH-independent Effects of Encaleret
Safety, Tolerability, and Efficacy of Encaleret in Participants With Autosomal Dominant Hypocalcemia (ADH) Type 1
A Study to Determine the Effects of NPSP795 on the Calcium-sensing Receptor in Subjects With Autosomal Dominant Hypocalcemia as Measured by PTH Levels and Blood Calcium Concentrations
Phase Legend
Key Insights
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.